Skip to content

Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique

Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02940977
Enrollment
120
Registered
2016-10-21
Start date
2016-10-01
Completion date
2019-03-30
Last updated
2018-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Adenoma, Prostatic Neoplasms

Keywords

Circulating tumor cell, Epithelial to mesenchymal transition, Prostate specific antigen (PSA), Partin table

Brief summary

1. To elucidate the role of CTC detection in the evaluation of risk level in PCa patients, and establish a mathematic model for predicting the pathological status. 2. To explore the possible subtle change in CTC condition after radical prostatectomy.

Detailed description

1. Detect and evaluate the CTC status (a total of 3 times: 1 day before sugery, 3/12 months after surgery) for all of the PCa patients enrolled. Analyze the CTC result with PSA level, needle biopsy and radiological imaging information. 2. Analyze the difference in CTC amount/Epithelial-Mesenchymal ratio between patients in different D'Amico risk level(low/intermediate/high). 3. Establish a mathematic model based on the CTC results and pathological condition observed in operation (OC, organ confined; EPE, extraprostatic extension; SVI, seminal vesicle invasion; LNI, lymph node invasion), and compare this model with the latest version of Partin table. 4. Detect and compare the CTC and PSA level 3/12 months after surgery. Evaluate the radiological condition in 12 months after blood draw.

Interventions

OTHERBlood draws

Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.

Sponsors

Shanghai Shen Kang Hospital Development Center
CollaboratorOTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Diagnosed with PCa by biopsy, for the first time. 2. Clinical assessed suitable for radical prostatectomy 3. Age ≥ 18 years, able to provide written informed consent 4. No prior systematic or regional treatment for PCa. 5. No neuro-endocrine differentiation or small cell PCa pattern. 6. ECOG status 0-1 7. Expected life span ≥ 12 months. 8. Multiorgan function (heart, lung, liver, kidney) able to tolerate radical prostatectomy, and meet the standard of this study.

Exclusion criteria

1. Severe concomitant disease or infection. 2. ALT or AST \> 2.5 ULN, or total bilirubin \> 1.5 ULN; Creatinine \>177umol/L(2.5mg/dL);Plt \< 100,000/uL, Neutrophil \<1,500/uL. 3. Known or suspected brain metastasis or leptomeningeal carcinomatosis. 4. Another malignancy in the last 5 years, excluding completely cured melanoma. 5. Severe cardiovascular disease, including: Myocardial infarct within 6 months; Uncontrolled angina pectoris within 3 months; Congestive heart failure; Ventricular arrhythmia history with clinical significance; Morbiz type Ⅱ or complete heart block 6. Major surgery (general anesthesia) within 4 weeks.

Design outcomes

Primary

MeasureTime frameDescription
Circulating tumor cell (CTC) total number and epithelial-intermediate-mesenchymal ratio detected by CTC enrichment and FISH technique1 day before operationThis step should be completed within the day when the peripheral venous blood is drawn.
Pathological findings (whether the patient has: 1.OC, organ confined; 2.EPE, extraprostatic extension; 3. SVI, seminal vesicle invasion; 4. LNI, lymph node invasion) during the radical prostectomy, confirmed by pathology section resultOn the day of operationThe pathology section evaluation will be done by two pathologists independently. A third pathology expert will join to make a final decision if opposite results are given by the two pathologists.
CTC total number and epithelial-intermediate-mesenchymal ratio detected by CTC enrichment and FISH technique3 months after operationThis step should be completed within the day when the peripheral venous blood is drawn.

Secondary

MeasureTime frameDescription
Prostate specific antigen (PSA) level measurement using peripheral venous blood3 months after operationThe blood should be drawn together with that for CTC detection
PSA level measurement using peripheral venous blood9 months after operationThe blood should be drawn together with that for CTC detection
Radiological evaluation including isotope bone scanning and pelvic magnetic resonance imaging (MRI) scan12 months after operationRadiological evaluation should be conducted after the blood is drawn for CTC and PSA detection.

Countries

China

Contacts

Primary ContactJun Qi, MD.
jasonqi@sh163.net021-20578080
Backup ContactJie Ding, MD.; Postdoc.
769233885@qq.com+8613564315425

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026